Deal facts
- Buyer
- Silo Pharma, Inc.
- Target
- Norsight Consulting Inc.
- Deal value
- Not disclosed
- Announced
- 2 October 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- shares
Sources
Silo Pharma, Inc. has agreed to acquire assets from Norsight Consulting Inc. in a transaction announced on 2 October 2026. Both companies are based in the United States and operate within the healthcare sector. The deal structure involves the transfer of specific assets rather than the purchase of equity, with Silo Pharma providing shares as the sole form of consideration. The financial value of the transaction has not been disclosed, and no specific currency or monetary figure has been reported. This asset sale represents a strategic move for Silo Pharma to integrate selected operational elements of Norsight Consulting into its existing portfolio. The arrangement highlights a focus on targeted asset acquisition within the US healthcare market, allowing the buyer to select specific components of the target business. As both entities are domestic to the US, the transaction does not involve cross-border regulatory complexities typically associated with international mergers. The primary consideration is equity-based, aligning the interests of the parties through shared ownership of the acquiring entity.
The transaction is currently at the firm intention stage, with no completion date reported.
Deal timeline
1 update- Firm intention
Silo Pharma, Inc. firm intention to acquire Norsight Consulting Inc.
Item 1.01 Entry into a Material Definitive Agreement. On October 1, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Norsight Consulting Inc., an Arkansas corporation (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Company agreed to purchase, certain software, technology, and related intellectual property, includi
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Rockwell Medical, Inc. to acquire Vantive's in-center hemodialysis business
Rockwell Medical, Inc. signed an Equity and Asset Purchase Agreement on November 2, 2026 with Vantive Limited, a Jersey company, to acquire Vantive's in-center hemodialy…
- Buyer
- Rockwell Medical, Inc.
- Target
- Vantive in-center hemodialysis business
- Deal value
- USD 125,000,000
- Deal type
- asset sale
Biossil Labs Inc. to acquire Theriva Biologics' ribaxamase and SYN-006 assets
Theriva Biologics, Inc. (NYSE American: TOVX) sold its ribaxamase program to Biossil Labs Inc., a corporation organized under the laws of Canada, under an Asset Purchase…
- Buyer
- Biossil Labs Inc.
- Target
- Theriva Biologics ribaxamase and SYN-006 assets
- Deal value
- USD 350,000
- Deal type
- asset sale
VoxelDox Therapeutics, Inc. to acquire Imunon, Inc.
VoxelDox Therapeutics, Inc. has agreed to acquire assets from Imunon, Inc. in a transaction announced on 21 October 2026. Both companies are based in the United States a…
- Buyer
- VoxelDox Therapeutics, Inc.
- Target
- Imunon, Inc.
- Deal value
- Not disclosed
- Deal type
- asset sale
Laboratory Corporation of America to acquire Myriad Genetics, Inc.
Laboratory Corporation of America has agreed to acquire Myriad Genetics, Inc. in a transaction structured as an asset sale. Both entities are based in the United States…
- Buyer
- Laboratory Corporation of America
- Target
- Myriad Genetics, Inc.
- Deal value
- Not disclosed
- Deal type
- asset sale
Silo Pharma, Inc. to acquire Larry King
Silo Pharma, Inc. entered into an asset purchase agreement on October 13, 2026 with Larry King, identified in the filing as the Seller. Under the agreement, King agreed…
- Buyer
- Silo Pharma, Inc.
- Target
- Larry King
- Deal value
- Not disclosed
- Deal type
- asset sale
Buyer history
Silo Pharma, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive